27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, thalidomide and dexamethasone, as a treatment option for untreated multiple myeloma in adults who are eligible for an autologous stem cell transplant.

Currently, most individuals with this condition receive a combination of bortezomib plus thalidomide and dexamethasone prior to their stem cell transplant.

Read Pharma Times article